• News
  • 2021 Benchmark framework to track pharma's pr...
News - published on 06 Oct 2020

2021 Benchmark framework to track pharma's progress against superbugs

The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial Resistance Benchmark provides the only independent measure of how pharmaceutical companies are responding. The methodology for 2021 prioritises the tracking of progress and a deeper exploration of the headwinds faced by biotechs driving novel R&D.

Explore further

Get in touch

Back to top |